Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
06 February 2020Website:
http://www.beamtx.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 01 Jul 2024 23:12:09 GMTDividend
Analysts recommendations
Institutional Ownership
BEAM Latest News
With the progression of modern medicine, and the continuous discoveries in the realm of gene editing, investing early in the technology could be a game changer for long-term returns if selecting the best gene editing stocks to buy. That's because unlike more standard therapeutics such as antibiotics, antivirals and vaccines gene editing is a permanent solution most of the time.
Beam Therapeutics (BEAM) doses the first patient in a phase I/II study, evaluating in vivo base editor BEAM-302 for treating alpha-1 antitrypsin deficiency.
CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the first patient was treated with BEAM-302, an investigational in vivo base editing medicine designed to precisely correct the underlying cause of severe alpha-1 antitrypsin deficiency (AATD), that is currently being evaluated in a Phase 1/2 clinical trial.
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock?
Beam Therapeutics will showcase data demonstrating the strong manufacturing process for BEAM-101 at the 2024 European Hematology Association (EHA) Hybrid Congress.
Beam Therapeutics (BEAM) has the perfect mix of factors that indicate it may exceed earnings expectations in its next report. Make sure you are ready with the important projections.
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock?
Beam Therapeutics Inc. NASDAQ: BEAM is a biotech company that specializes in developing precision gene therapies for hereditary diseases. The medical sector company is a pioneer in a proprietary gene-editing technique called base editing.
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in the following upcoming investor conferences:
Beam Therapeutics Inc. (BEAM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What type of business is Beam Therapeutics?
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
What sector is Beam Therapeutics in?
Beam Therapeutics is in the Healthcare sector
What industry is Beam Therapeutics in?
Beam Therapeutics is in the Biotechnology industry
What country is Beam Therapeutics from?
Beam Therapeutics is headquartered in United States
When did Beam Therapeutics go public?
Beam Therapeutics initial public offering (IPO) was on 06 February 2020
What is Beam Therapeutics website?
https://www.beamtx.com
Is Beam Therapeutics in the S&P 500?
No, Beam Therapeutics is not included in the S&P 500 index
Is Beam Therapeutics in the NASDAQ 100?
No, Beam Therapeutics is not included in the NASDAQ 100 index
Is Beam Therapeutics in the Dow Jones?
No, Beam Therapeutics is not included in the Dow Jones index
When does Beam Therapeutics report earnings?
The next expected earnings date for Beam Therapeutics is 08 August 2024